Key result
Innovative trial designs for pulmonary arterial hypertension are needed to assess efficacy signals early and maximize efficiency in pursuing agents with the greatest potential for cure.
Key points are not available for this paper at this time.
Design
Review
The article highlights the need for innovative trial designs in pulmonary arterial hypertension to maximize efficiency and identify curative agents.
This article elaborates on the phases of drug development and trial design for pulmonary arterial hypertension, emphasizing the need for learning trials to assess efficacy signals before confirming trials. In this new era in pulmonary arterial hypertension, we need to reconsider innovative trial designs to maximize efficiency and pursue agents with the greatest potential for cure.
No takes yet. Share an insight, caveat, or question.
Mardi Gomberg‐Maitland (2008) studied this question. Innovative trial designs for pulmonary arterial hypertension are needed to assess efficacy signals early and maximize efficiency in pursuing agents with the greatest potential for cure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: